Indications for: DETROL LA
Overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence.
Swallow whole. 4mg once daily; may decrease to 2mg once daily. Concomitant strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, ritonavir), or severe renal or mild to moderate hepatic dysfunction: 2mg once daily. Severe hepatic impairment, CrCl<10mL/min: not recommended.
DETROL LA Contraindications:
Urinary or gastric retention. Uncontrolled narrow-angle glaucoma. Fesoterodine fumarate allergy.
DETROL LA Warnings/Precautions:
Bladder outflow obstruction. GI obstruction (eg, pyloric stenosis). Decreased GI motility. Discontinue if angioedema occurs. Monitor for anticholinergic CNS effects (esp. when starting treatment and after dose increases). Narrow-angle glaucoma. Myasthenia gravis. History of QT prolongation. Pregnancy. Nursing mothers: not recommended.
DETROL LA Classification:
DETROL LA Interactions:
Plasma levels increased by CYP3A4 inhibitors (see Adult dose). Caution with Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmics. Additive anticholinergic effects with other anticholinergics.
Dry mouth/eyes, headache, constipation, abdominal pain, dyspepsia, fatigue, dizziness, somnolence, sinusitis, abnormal vision, anxiety, dysuria, other anticholinergic effects; anaphylaxis, angioedema.
Renal (primarily), fecal.
Generic Drug Availability:
LA—30, 90, 500; Tabs—60, 500